PMN
ProMIS Neurosciences
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
News
- ProMIS Neurosciences reports positive blinded six-month interim safety and biomarker data for PMN310 in the Phase 1b PRECISE-AD Alzheimer's trialJul 28, 2026
- ProMIS Neurosciences exceeds enrollment target in PRECISE-AD Phase 1b Alzheimer's trialDec 18, 2025
- ProMIS Neurosciences receives DSMB approval to advance to final dose escalation cohort in Phase 1b Alzheimer's trial of PMN310Sep 3, 2025
- ProMIS Neurosciences granted FDA Fast Track designation for PMN310 in Alzheimer's disease treatmentJul 21, 2025